Release Date: December 10, 2022
Expiration Date: February 1, 2023
Activity Overview
This educational activity is an archive of the live virtual presentation held on December 9, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This activity is directed toward a global audience of medical oncologists, hematologic oncologists, hematologists, NP/PAs, nurses, and other healthcare professionals involved in the treatment of GvHD.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain the pathological mechanisms of acute and chronic GvHD underlying the rationale for therapeutic approaches to prevent and treat these post-transplant complications
- Evaluate the latest clinical evidence for therapeutic strategies investigated for the prevention and treatment of acute/chronic GvHD
- Apply strategies to promote the timely recognition and mitigation of treatment-related toxicities in patients at risk of developing GvHD or who are treated for GvHD
- Translate evidence-based approaches for the prophylaxis and treatment of acute and chronic GvHD into personalized treatment plans for patients after transplantation, to prevent or manage these post-transplant complications
Corey Cutler, MD, MPH, FRCPC
Associate Professor of Medicine
Harvard Medical School
Medical Director, Adult Stem Cell Transplantation Program
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Consultant: Advisory Board/Consultant for: Mallinckrodt, Sanofi, CSL Behring, CTI BioPharma, Equillium, Bristol Myers Squibb, Janssen, Incyte, Deciphera Pharmaceuticals, Editas Medicine, Pfizer, CareDx, Omeros, Jazz Pharmaceuticals, Cimeio Therapeutics, Oxford Immune Algorithmics; Other: Data and Safety Monitoring Board (DSMB): AlloVir, Da Volterra, BioLineRx, Pluristem Therapeutics, Angiocrine Biosciences.
Sergio Giralt, MD, FACP, FASTCT
Professor of Medicine
Weill Cornell Medical College
Melvin Berlin Family Chair in Myeloma Research
Deputy Head, Division of Hematologic Malignancies
Attending Physician, Adult BMT Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY
Disclosures: Grant/Research Support: Miltenyi Biotec; Takeda Pharmaceutical Co; Celgene Corp; Amgen Inc; Sanofi; Johnson and Johnson, Inc; Actinium Pharmaceuticals, Inc.; Other: Advisory boards for: Kite Pharmaceuticals, Inc; Celgene Corp; Sanofi; Novartis; Johnson and Johnson, Inc; Amgen Inc; Takeda Pharmaceutical Co; Jazz Pharmaceuticals, Inc; Actinium Pharmaceuticals.
Catherine Lee, MD
Associate Professor of Medicine, Division of Hematology & Hematologic Malignancies
The University of Utah Transplant & Cellular Therapy Program at Huntsman Cancer Institute
Associate Professor of Medicine
Division of Hematology & Hematologic Malignancies
The University of Utah Transplant and Cellular Therapy Program at Huntsman Cancer Institute and Primary
Children's Hospital
Salt Lake City, UT
Disclosures: Grant/Research Support: Incyte Corporation; Consultant: Incyte Corporation, Kadmon Corporation, Kite Pharma, Bristol Myers Squibb, Fresenius Medical Care, Fresenius Kabi, CareDx; Speakers’ Bureau: Kite Pharma; Other: Incyte Corporation, study steering committee.
Doris M. Ponce, MD
Associate Professor of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant/Research Support: Incyte Corporation.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
